FMP
IDEAYA Biosciences, Inc.
IDYA
NASDAQ
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
23.14 USD
-0.01 (-0.04322%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
4.34B
4.17B
4.62B
5.62B
5.66B
6.08B
6.52B
7B
7.51B
8.07B
-
-3.81
10.69
21.81
0.66
7.34
7.34
7.34
7.34
1.73B
1.38B
2.16B
2.17B
2.11B
2.38B
2.55B
2.74B
2.94B
3.15B
39.92
32.99
46.81
38.53
37.22
39.09
39.09
39.09
39.09
631M
168M
1.05B
823M
769M
844.33M
906.29M
972.81M
1.04B
1.12B
14.55
4.03
22.68
14.63
13.58
13.9
13.9
13.9
13.9
1.1B
1.21B
1.11B
1.34B
1.34B
1.53B
1.64B
1.76B
1.89B
2.03B
25.37
28.96
24.13
23.9
23.64
25.2
25.2
25.2
25.2
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
1.53B
1.03B
895M
1.04B
775M
1.36B
1.46B
1.56B
1.68B
1.8B
35.4
24.81
19.38
18.47
13.69
22.35
22.35
22.35
22.35
560M
684M
620M
699M
525M
783.2M
840.68M
902.38M
968.61M
1.04B
12.92
16.4
13.43
12.43
9.27
12.89
12.89
12.89
12.89
32M
37M
63M
53M
45M
57.45M
61.66M
66.19M
71.04M
76.26M
0.74
0.89
1.36
0.94
0.79
0.95
0.95
0.95
0.95
289M
334M
347M
400M
390M
439.82M
472.09M
506.74M
543.93M
583.85M
6.67
8.01
7.52
7.11
6.89
7.24
7.24
7.24
7.24
-907M
-824M
-908M
-1.07B
-1.18B
-1.22B
-1.31B
-1.4B
-1.51B
-1.62B
-20.92
-19.76
-19.67
-19.06
-20.9
-20.06
-20.06
-20.06
-20.06
27.78
171.4M
9.19
-4.3
7.74B
4.76B
12.5B
61.91
38.09
6.54
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
4.34B
4.17B
4.62B
5.62B
5.66B
6.08B
6.52B
7B
7.51B
8.07B
1.73B
1.38B
2.16B
2.17B
2.11B
2.38B
2.55B
2.74B
2.94B
3.15B
631M
168M
1.05B
823M
769M
844.33M
906.29M
972.81M
1.04B
1.12B
146.86
146.86
146.86
146.86
146.86
146.86
146.86
146.86
146.86
146.86
283.66M
231.23M
843.89M
55.33M
-360.33M
392.24M
421.02M
451.92M
485.09M
520.69M
1.1B
1.21B
1.11B
1.34B
1.34B
1.53B
1.64B
1.76B
1.89B
2.03B
560M
684M
620M
699M
525M
783.2M
840.68M
902.38M
968.61M
1.04B
32M
37M
63M
53M
45M
57.45M
61.66M
66.19M
71.04M
76.26M
289M
334M
347M
400M
390M
439.82M
472.09M
506.74M
543.93M
583.85M
-907M
-824M
-908M
-1.07B
-1.18B
-1.22B
-1.31B
-1.4B
-1.51B
-1.62B
173.66M
531.23M
1.1B
311.33M
-33.33M
483.66M
726.78M
780.12M
837.37M
898.82M
6.54
6.54
6.54
6.54
6.54
453.97M
640.29M
645.09M
649.93M
654.8M
3.04B
6.54
930.28M
30.61B
22.3B
25.35B
6.96B
18.38B
171.4M
107.26
107.26 0.741%